143 related articles for article (PubMed ID: 35624380)
1. Pembrolizumab as a first line therapy in a patient with extensive mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case.
Farhat R; Asna N; Avraham Y; Khater A; Asakla M; Safia A; Szvalb S; Elkhatib N; Merchavy S
Discov Oncol; 2022 May; 13(1):37. PubMed ID: 35624380
[TBL] [Abstract][Full Text] [Related]
2. Prolonged response to checkpoint inhibitor therapy in two metastatic mucoepidermoid salivary gland carcinoma cases: a research report.
Pharaon RR; Gernon T; Chang S; Vora N; Villaflor VM; Bell D; Afkhami M; Amini A; Sampath S; Kang R; Maghami EG; Massarelli E
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483880
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.
Cohen RB; Delord JP; Doi T; Piha-Paul SA; Liu SV; Gilbert J; Algazi AP; Damian S; Hong RL; Le Tourneau C; Day D; Varga A; Elez E; Wallmark J; Saraf S; Thanigaimani P; Cheng J; Keam B
Am J Clin Oncol; 2018 Nov; 41(11):1083-1088. PubMed ID: 29462123
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
7. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: A case-control study.
Sawabe M; Ito H; Takahara T; Oze I; Kawakita D; Yatabe Y; Hasegawa Y; Murakami S; Matsuo K
Cancer; 2018 Jan; 124(1):118-124. PubMed ID: 28881386
[TBL] [Abstract][Full Text] [Related]
10. Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers.
Sato R; Yamaki H; Komatsuda H; Wakisaka R; Inoue T; Kumai T; Takahara M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539539
[TBL] [Abstract][Full Text] [Related]
11. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Descourt R; Chouaid C; Pérol M; Besse B; Greillier L; Bylicki O; Ricordel C; Guisier F; Gervais R; Schott R; Auliac JB; Robinet G; Decroisette C
Future Oncol; 2021 Aug; 17(23):3007-3016. PubMed ID: 34156285
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of PD-1 inhibitors in patients with salivary gland carcinoma: A retrospective observational study.
Sato R; Kumai T; Ishida Y; Yuasa R; Kubota A; Wakisaka R; Komatsuda H; Yamaki H; Wada T; Harabuchi Y
Laryngoscope Investig Otolaryngol; 2022 Dec; 7(6):1808-1813. PubMed ID: 36544935
[TBL] [Abstract][Full Text] [Related]
13. Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report.
Ikarashi D; Kitano S; Ishida K; Nakatsura T; Shimodate H; Tsuyukubo T; Tamura D; Kato R; Sugai T; Obara W
Front Oncol; 2020; 10():564714. PubMed ID: 33072593
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer.
Zhang L; Mai W; Jiang W; Geng Q
Front Surg; 2020; 7():601805. PubMed ID: 33330611
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B
Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
